# GEMMA Biotherapeutics

> GEMMA Biotherapeutics (GEMMABio) is a Philadelphia-based gene therapy company spun out of the University of Pennsylvania and founded by AAV pioneer James M. Wilson. Launched in October 2024 with $34 million in seed funding, GEMMABio builds the research, manufacturing, and product-development infrastructure to move adeno-associated virus (AAV) gene therapies from the bench to the bedside faster and more affordably - with a focus on rare and ultra-orphan inherited diseases and a stated commitment to global patient access.

- **Founded:** 2024
- **Headquarters:** Philadelphia, Pennsylvania, United States
- **Founders:** James M. Wilson (Founder, President & CEO)
- **Team size:** ~64 employees
- **Products:** AAV gene therapy platform, Translational research & product development, Rare Therapeutics, Inc. (RareTx)
- **Notable:** Raised $34 million seed round in December 2024 co-led by four life-science venture firms., Founded by James M. Wilson, a pioneer whose lab discovered and engineered the AAV vectors now central to the gene therapy field., Launched clinical-stage subsidiary Rare Therapeutics, Inc. in October 2025 targeting ultra-orphan lysosomal storage diseases.

## Products & services

- **AAV gene therapy platform** — Proprietary adeno-associated virus (AAV) vectors engineered as gene transfer vehicles - the technology lineage pioneered in James Wilson's lab at Penn.
- **Translational research & product development** — End-to-end research, GxP operations, manufacturing, regulatory affairs, and clinical development services that move rare-disease gene therapies from discovery toward the clinic.
- **Rare Therapeutics, Inc. (RareTx)** — A clinical-stage subsidiary launched October 2025 to develop and deliver gene therapies for ultra-orphan lysosomal storage diseases including GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy.

## Achievements

- Raised $34 million seed round in December 2024 co-led by four life-science venture firms.
- Founded by James M. Wilson, a pioneer whose lab discovered and engineered the AAV vectors now central to the gene therapy field.
- Launched clinical-stage subsidiary Rare Therapeutics, Inc. in October 2025 targeting ultra-orphan lysosomal storage diseases.
- Established regional access strategy with hubs planned in Brazil and Abu Dhabi.

## Latest updates

- **2025-10** — Launched Rare Therapeutics, Inc. (RareTx), a clinical-stage company for ultra-orphan lysosomal storage diseases (GM1 gangliosidosis, Krabbe disease, MLD).
- **2024-12** — Closed $34 million seed financing to fund operational expansion and its rare-disease gene therapy mission.
- **2024-10** — Company launched as a University of Pennsylvania spinout led by James M. Wilson.

## Links

- Website: https://gemmabiotx.com
- LinkedIn: https://www.linkedin.com/company/gemmabiotx

---

Profile page: https://yespress.io/gemma-biotherapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-05